Cargando…
SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831628/ https://www.ncbi.nlm.nih.gov/pubmed/32703727 http://dx.doi.org/10.1016/j.dld.2020.06.047 |
| _version_ | 1783641657897385984 |
|---|---|
| author | Bardasi, Giulia Alvisi, Patrizia |
| author_facet | Bardasi, Giulia Alvisi, Patrizia |
| author_sort | Bardasi, Giulia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7831628 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78316282021-01-26 SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy? Bardasi, Giulia Alvisi, Patrizia Dig Liver Dis Correspondence Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2020-11 2020-07-11 /pmc/articles/PMC7831628/ /pubmed/32703727 http://dx.doi.org/10.1016/j.dld.2020.06.047 Text en © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Bardasi, Giulia Alvisi, Patrizia SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy? |
| title | SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy? |
| title_full | SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy? |
| title_fullStr | SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy? |
| title_full_unstemmed | SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy? |
| title_short | SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy? |
| title_sort | sars-cov-2 infection in severe pediatric crohn's disease. what about anti-tumor necrosis factor α therapy? |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831628/ https://www.ncbi.nlm.nih.gov/pubmed/32703727 http://dx.doi.org/10.1016/j.dld.2020.06.047 |
| work_keys_str_mv | AT bardasigiulia sarscov2infectioninseverepediatriccrohnsdiseasewhataboutantitumornecrosisfactoratherapy AT alvisipatrizia sarscov2infectioninseverepediatriccrohnsdiseasewhataboutantitumornecrosisfactoratherapy |